Make an Inquiry
Accelerating Kidney Fibrosis Drug Development

Fibrosis of the kidney presents a significant barrier to effective treatment of chronic kidney diseases, driving the urgent need for innovative therapeutic solutions. Ace Therapeutics is a specialized partner in preclinical drug development, dedicated exclusively to advancing novel therapies for renal fibrosis. Ace Therapeutics offers a comprehensive suite of preclinical services, encompassing target validation, lead optimization, pharmacology, and IND-enabling studies. Our scientific team brings deep expertise in renal biology and fibrosis pathophysiology, supported by state-of-the-art in vitro and in vivo platforms tailored to kidney disease models. We integrate rigorous experimental design with advanced biomarker analysis and translational endpoints to optimize candidate selection and de-risk development pipelines. With a strong commitment to regulatory compliance and industry best practices, Ace Therapeutics ensures that all studies meet global standards, facilitating seamless progression to clinical development. By leveraging scientific excellence, cutting-edge technology, and a focused therapeutic approach, Ace Therapeutics accelerates the discovery and development of transformative therapies for kidney fibrosis.

What is Kidney FibrosisTargets for Kidney FibrosisDrug Discovery and Development ServicesWhy Choose Us

What is Kidney Fibrosis

Renal fibrosis is a pathological process marked by the excessive accumulation of extracellular matrix components, primarily collagen, within the kidney tissue. It represents a final common pathway in the progression of virtually all chronic kidney diseases (CKD), regardless of the initial cause. The development of renal fibrosis involves persistent injury to the kidneys, maladaptive repair responses, chronic inflammation, and activation of fibrogenic signaling pathways such as transforming growth factor-beta (TGF-β). These mechanisms lead to the activation of myofibroblasts and increased deposition of fibrous tissue, which disrupts normal kidney architecture and impairs function. Types of renal fibrosis include interstitial fibrosis, glomerulosclerosis, perivascular fibrosis, and fibrosis associated with tubular atrophy. Clinically, renal fibrosis manifests as progressive CKD, with symptoms such as proteinuria, reduced glomerular filtration rate (GFR), hypertension, and electrolyte imbalances. Diagnosis relies on a combination of clinical assessment, laboratory tests (including serum creatinine and estimated GFR), and imaging studies, though definitive confirmation requires renal biopsy with histopathological evaluation. The extent of fibrosis is a key prognostic factor for CKD progression to end-stage renal disease (ESRD). Management focuses on controlling underlying risk factors (e.g., diabetes, hypertension), slowing CKD progression, and addressing complications, while research continues into antifibrotic therapies and non-invasive diagnostic methods.

Learn More

Targets for Kidney Fibrosis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
G protein-coupled receptor 68 GPR68
Mitogen-activated protein kinase p38 (MAPK p38) (nonspecified subtype)

Kidney fibrosis arises from a complex interplay of molecular pathways, with several key therapeutic targets identified across diverse mechanistic categories. Central among these are G protein-coupled receptors such as ADORA3 and AGTR2, which modulate inflammation, fibroblast activation, and the renin-angiotensin system. Enzymes like ALOX5, CYP4A11, CYP4F2, and EPHX2 drive the biosynthesis and metabolism of lipid mediators, influencing inflammatory signaling and oxidative stress. Transcriptional and epigenetic regulators, notably BRD4 and SRF, orchestrate the gene expression programs underlying myofibroblast differentiation and extracellular matrix (ECM) production. Direct regulators of ECM dynamics, including CCN2 (CTGF) and DDR1, promote fibroblast activation and collagen deposition, while KEAP1 controls the cellular redox response through NRF2 signaling, impacting injury and fibrogenesis.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service for kidney fibrosis accelerates drug discovery by providing comprehensive screening and mechanistic characterization of candidate compounds. Utilizing advanced biochemical, enzymatic, receptor-binding, and cell-based assays, we evaluate efficacy, target engagement, and molecular pathways such as TGF-β, ECM deposition, and inflammation. Key parameters measured include IC-50, EC-50, Ki, Kd, and MIC, ensuring robust pharmacological profiling. Our expertise covers a wide array of fibrosis-relevant targets, enabling precise lead optimization and data-driven decision-making. This service empowers clients to rapidly identify and optimize novel anti-fibrotic therapeutics for kidney disease with confidence and scientific rigor.

Adenosine A3 Receptor Arachidonate 5-Lipoxygenase
Bromodomain Containing 4 Cellular Communication Network Factor 2
Cytochrome P450 Family 4 Subfamily A Member 11 Cytochrome P450 Family 4 Subfamily F Member 2
Delta 4-Desaturase, Sphingolipid 1 Discoidin Domain Receptor Tyrosine Kinase 1
Epoxide Hydrolase 2 Homeodomain Interacting Protein Kinase 2

Learn More

Why Choose Us

Choosing Ace Therapeutics means partnering with a team deeply committed to advancing the field of Kidney fibrosis research and drug development. Our specialized expertise in this area is supported by a dedicated team of scientists and clinicians who bring years of experience and insight to every project. At Ace Therapeutics, we utilize advanced technology platforms that enable us to deliver precise, reliable, and innovative solutions tailored to the unique challenges of Kidney fibrosis therapeutics. Our proven track record in preclinical drug development speaks to our reliability and the trust our clients place in us. We adhere to the highest quality standards and maintain rigorous regulatory compliance throughout every stage of our work, ensuring that all studies and processes meet or exceed industry expectations. Above all, Ace Therapeutics is driven by a genuine commitment to improving patient outcomes by accelerating the development of novel therapies for Kidney fibrosis diseases. When you choose Ace Therapeutics, you are choosing professionalism, reliability, and a partner dedicated to making a meaningful difference in the lives of patients.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for kidney fibrosis?

A: Preclinical research for kidney fibrosis faces several unique challenges, including the complexity of disease mechanisms, the lack of highly predictive animal models, and difficulties in identifying translatable biomarkers. Our company addresses these challenges by utilizing a range of validated in vitro and in vivo models, incorporating advanced imaging and molecular techniques, and collaborating with academic experts to ensure clinical relevance.

Q: What are the key regulatory considerations during preclinical development of anti-fibrotic drugs for the kidney?

A: Regulatory agencies require robust evidence of safety, efficacy, and mechanism of action before allowing progression to clinical trials. For kidney fibrosis, this includes demonstrating target engagement, dose rationale, and renal-specific toxicology. We help clients navigate these requirements by designing comprehensive preclinical packages, providing detailed documentation, and supporting interactions with regulatory authorities such as the FDA and EMA.

Q: What technical aspects are critical in preclinical research for kidney fibrosis drug candidates?

A: Critical technical aspects include the selection of appropriate disease models (such as UUO, 5/6 nephrectomy, or adenine-induced fibrosis), use of sensitive biomarkers for early detection of fibrosis, and implementation of advanced histopathological and molecular analyses. Our team leverages cutting-edge technologies, including multi-omics and quantitative imaging, to generate high-quality, reproducible data.

Q: How do timeline and cost considerations impact preclinical development of kidney fibrosis therapies?

A: Preclinical development timelines for kidney fibrosis therapies typically range from 12 to 24 months, depending on the complexity of studies required. Costs are influenced by the choice of models, endpoints, and regulatory requirements. We work closely with clients to optimize study design, streamline workflows, and provide transparent budgeting to ensure projects remain on schedule and within budget.

Q: What are the key success factors in preclinical drug development for kidney fibrosis?

A: Success in preclinical kidney fibrosis drug development relies on selecting clinically relevant models, employing robust and sensitive endpoints, ensuring regulatory compliance, and maintaining clear communication with stakeholders. Our expertise in translational science, regulatory strategy, and project management enables us to deliver high-quality data and accelerate the path to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.